Copy to clipboard 
Xenco Medical debuted a convergent technology bridging digital health and biomaterials, the TrabeculeX Continuum. Comprising the FDA-cleared TrabeculeX Bioactive Matrix and the TrabeculeX Recovery App, the TrabeculeX Continuum is claimed to be the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s biomaterial implantation and postoperative journey.
Empowering surgeons who have implanted Xenco Medical’s FDA-cleared TrabeculeX Bioactive Matrix to enroll patients in the TrabeculeX Recovery App and engage in both Remote Therapeutic Monitoring and asynchronous video and text messaging, the TrabeculeX Continuum is an intersection of regenerative medicine and digital health
Engineered to harness the hydroxycarbonate apatite-forming capabilities of bioglass in every TrabeculeX Bioactive Matrix, the regenerative biomaterial included in the TrabeculeX Continuum has been designed by Xenco Medical to conduct three-dimensional bone-formation. Leveraging a complex surface topography, the TrabeculeX Bioactive Matrix’s architecture begins at the sub-micron scale and spans to the entire lattice itself.
Bridging the journey from biomaterial implantation to full physical rehabilitation, the TrabeculeX Recovery App enables surgeons who’ve used a TrabeculeX Bioactive Matrix strip in their patient to prescribe and remotely monitor patient-specific physical rehabilitation plans, with the ability to engage in asynchronous video and text messaging.
“As a surgical technology company devoted not only to our patients’ intraoperative care but to their longitudinal recovery, we’ve committed ourselves to dissolving the barriers that currently exist in the siloed path from surgery to rehabilitation. With the TrabeculeX Continuum, we’re excited to introduce a connective technology that recognizes the full arc of a patient’s journey rather than a single instance of care,” said Xenco Medical Founder and CEO Jason Haider.
Source: Xenco Medical
Xenco Medical debuted a convergent technology bridging digital health and biomaterials, the TrabeculeX Continuum. Comprising the FDA-cleared TrabeculeX Bioactive Matrix and the TrabeculeX Recovery App, the TrabeculeX Continuum is claimed to be the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s...
Xenco Medical debuted a convergent technology bridging digital health and biomaterials, the TrabeculeX Continuum. Comprising the FDA-cleared TrabeculeX Bioactive Matrix and the TrabeculeX Recovery App, the TrabeculeX Continuum is claimed to be the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s biomaterial implantation and postoperative journey.
Empowering surgeons who have implanted Xenco Medical’s FDA-cleared TrabeculeX Bioactive Matrix to enroll patients in the TrabeculeX Recovery App and engage in both Remote Therapeutic Monitoring and asynchronous video and text messaging, the TrabeculeX Continuum is an intersection of regenerative medicine and digital health
Engineered to harness the hydroxycarbonate apatite-forming capabilities of bioglass in every TrabeculeX Bioactive Matrix, the regenerative biomaterial included in the TrabeculeX Continuum has been designed by Xenco Medical to conduct three-dimensional bone-formation. Leveraging a complex surface topography, the TrabeculeX Bioactive Matrix’s architecture begins at the sub-micron scale and spans to the entire lattice itself.
Bridging the journey from biomaterial implantation to full physical rehabilitation, the TrabeculeX Recovery App enables surgeons who’ve used a TrabeculeX Bioactive Matrix strip in their patient to prescribe and remotely monitor patient-specific physical rehabilitation plans, with the ability to engage in asynchronous video and text messaging.
“As a surgical technology company devoted not only to our patients’ intraoperative care but to their longitudinal recovery, we’ve committed ourselves to dissolving the barriers that currently exist in the siloed path from surgery to rehabilitation. With the TrabeculeX Continuum, we’re excited to introduce a connective technology that recognizes the full arc of a patient’s journey rather than a single instance of care,” said Xenco Medical Founder and CEO Jason Haider.
Source: Xenco Medical
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
